PRAME expression and promoter hypomethylation in epithelial ovarian cancer

Oncotarget

Volumn 7, Issue 29, 2016, Pages 45352-45369

  Zhang, Wa ^a,d   Barger, Carter J ^a   Eng, Kevin H ^c   Klinkebiel, David ^b   Link, Petra A ^c   Omilian, Angela ^c   Bshara, Wiam ^c   Odunsi, Kunle ^c   Karpf, Adam R ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Cancer testis antigens; DNA methylation; Epithelial ovarian cancer; High grade serous cancer; PRAME

Indexed keywords

CANCER TESTIS ANTIGEN; DNA METHYLTRANSFERASE; GENOMIC DNA; MESSENGER RNA; PROTEIN LINE 1; PROTEIN PRAME; TUMOR MARKER; UNCLASSIFIED DRUG; DNA (CYTOSINE 5) METHYLTRANSFERASE 1; PRAME PROTEIN, HUMAN; TUMOR ANTIGEN;

ADULT; ARTICLE; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; COPY NUMBER VARIATION; CYTOPLASM; DNA METHYLATION; ENZYME ACTIVATION; GENE DISRUPTION; GENE LOCUS; GENE TARGETING; GENETIC CORRELATION; HETEROZYGOSITY; HIGH GRADE SEROUS CANCER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MIDDLE AGED; OVARY CANCER; OVARY CARCINOMA; PROMOTER REGION; PROTEIN EXPRESSION; ANTAGONISTS AND INHIBITORS; FEMALE; GENE DOSAGE; GENETICS; NEOPLASM; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANTIGENS, NEOPLASM; CELL LINE, TUMOR; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1; DNA METHYLATION; FEMALE; GENE DOSAGE; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER;

EID: 84979946001     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9977     Document Type: Article

References (57)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer. 2010; 127:2893-2917.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65:5-29.
3. Prat J. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014; 124:1-5.
4. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474:609-615.
5. Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, et al. Wholegenome characterization of chemoresistant ovarian cancer. Nature. 2015; 521:489-494.
6. Ikeda H, Lethe B, Lehmann F, van Baren N, Baurain JF, de Smet C, Chambost H, Vitale M, Moretta A, Boon T, Coulie PG. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity. 1997; 6:199-208.
7. Wadelin F, Fulton J, McEwan PA, Spriggs KA, Emsley J, Heery DM. Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia. Molecular cancer. 2010; 9:226.
8. Redner RL. PRAMEing a picture of differentiation therapy for AML? Clinical cancer research. 2013; 19:2277-2279.
9. Gerard C, Baudson N, Ory T, Segal L, Louahed J. A Comprehensive Preclinical Model Evaluating the Recombinant PRAME Antigen Combined With the AS15 Immunostimulant to Fight Against PRAME-expressing Tumors. Journal of immunotherapy. 2015; 38:311-320.
10. Spel L, Boelens JJ, van der Steen DM, Blokland NJ, van Noesel MM, Molenaar JJ, Heemskerk MH, Boes M, Nierkens S. Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma. Oncotarget. 2015; 6:35770-35781. doi: 10.18632/oncotarget.5657.
11. Hermesa N, Kewitza S, Staege MS. Preferentially Expressed Antigen in Melanoma (PRAME) and the PRAME family of Leucine-Rich Repeat Proteins". Current cancer drug targets. 2015.
12. Akers SN, Odunsi K, Karpf AR. Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy. Future oncology. 2010; 6:717-732.
13. Woloszynska-Read A, James SR, Link PA, Yu J, Odunsi K, Karpf AR. DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. Cancer Immun. 2007; 7:21.
14. Ortmann CA, Eisele L, Nuckel H, Klein-Hitpass L, Fuhrer A, Duhrsen U, Zeschnigk M. Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia. Annals of hematology. 2008; 87:809-818.
15. Qian J, Zhu ZH, Lin J, Ming Yao DM, Li Y, Yang J, Wang CZ. Hypomethylation of PRAME promoter is associated with poor prognosis in myelodysplastic syndrome. British journal of haematology. 2011; 154:153-155.
16. Atanackovic D, Luetkens T, Kloth B, Fuchs G, Cao Y, Hildebrandt Y, Meyer S, Bartels K, Reinhard H, Lajmi N, Hegewisch-Becker S, Schilling G, Platzbecker U, et al. Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia. American journal of hematology. 2011; 86:918-922.
17. Gutierrez-Cosio S, de la Rica L, Ballestar E, Santamaria C, Sanchez-Abarca LI, Caballero-Velazquez T, Blanco B, Calderon C, Herrero-Sanchez C, Carrancio S, Ciudad L, Canizo C, San Miguel JF, et al. Epigenetic regulation of PRAME in acute myeloid leukemia is different compared to CD34+ cells from healthy donors: effect of 5-AZA treatment. Leukemia research. 2012; 36:895-899.
18. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo JA, Navarro G, Jose-Eneriz ES, Garate L, Cordeu L, Cervantes F, Prosper F, Heiniger A, Torres A. Epigenetic regulation of PRAME gene in chronic myeloid leukemia. Leukemia research. 2007; 31:1521-1528.
19. Sigalotti L, Fratta E, Coral S, Tanzarella S, Danielli R, Colizzi F, Fonsatti E, Traversari C, Altomonte M, Maio M. Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine. Cancer research. 2004; 64:9167-9171.
20. Pollack SM, Li Y, Blaisdell MJ, Farrar EA, Chou J, Hoch BL, Loggers ET, Rodler E, Eary JF, Conrad EU, 3rd, Jones RL, Yee C. NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine. PloS one. 2012; 7:e32165.
21. Yao Y, Zhou J, Wang L, Gao X, Ning Q, Jiang M, Wang J, Yu L. Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine. PloS one. 2013; 8:e70522.
22. Yan M, Himoudi N, Basu BP, Wallace R, Poon E, Adams S, Hasan F, Xue SA, Wilson N, Dalgleish A, Williams O, Anderson J. Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2'-Deoxycytidine. Cancer immunology, immunotherapy. 2011; 60:1243-1255.
23. Odunsi K, Matsuzaki J, James SR, Mhawech-Fauceglia P, Tsuji T, Miller A, Zhang W, Akers SN, Griffiths EA, Miliotto A, Beck A, Batt CA, Ritter G, et al. Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer. Cancer immunology research. 2014; 2:37-49.
24. Epping MT, Wang L, Edel MJ, Carlee L, Hernandez M, Bernards R. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell. 2005; 122:835-847.
25. Bullinger L, Schlenk RF, Gotz M, Botzenhardt U, Hofmann S, Russ AC, Babiak A, Zhang L, Schneider V, Dohner K, Schmitt M, Dohner H, Greiner J. PRAMEinduced inhibition of retinoic acid receptor signalingmediated differentiation-a possible target for ATRA response in AML without t(15;17). Clinical cancer research. 2013; 19:2562-2571.
26. Kewitz S, Staege MS. Knock-down of PRAME increases retinoic acid signaling and cytotoxic drug sensitivity of Hodgkin lymphoma cells. PloS one. 2013; 8:e55897.
27. Xu Y, Yue Q, Wei H, Pan G. PRAME induces apoptosis and inhibits proliferation of leukemic cells in vitro and in vivo. International journal of clinical and experimental pathology. 2015; 8:14549-14555.
28. Yan H, Zhao RM, Wang ZJ, Zhao FR, Wang SL. Knockdown of PRAME enhances adriamycin-induced apoptosis in chronic myeloid leukemia cells. European review for medical and pharmacological sciences. 2015; 19:4827-4834.
29. Goodison S, Urquidi V. The cancer testis antigen PRAME as a biomarker for solid tumor cancer management. Biomarkers in medicine. 2012; 6:629-632.
30. Field MG, Decatur CL, Kurtenbach S, Gezgin G, van der Velden PA, Jager MJ, Kozak KN, Harbour JW. PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma. Clinical cancer research. 2016; 22:1234-1242.
31. Ercolak V, Paydas S, Bagir E, Ergin M, Seydaoglu G, Celik H, Yavuz B, Tanriverdi K, Gunaldi M, Afsar CU, Duman BB. PRAME Expression and Its Clinical Relevance in Hodgkin's Lymphoma. Acta haematologica. 2015; 134:199-207.
32. Brenne K, Nymoen DA, Reich R, Davidson B. PRAME (preferentially expressed antigen of melanoma) is a novel marker for differentiating serous carcinoma from malignant mesothelioma. American journal of clinical pathology. 2012; 137:240-247.
33. Partheen K, Levan K, Osterberg L, Horvath G. Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors. European journal of cancer. 2006; 42:2846-2854.
34. Partheen K, Levan K, Osterberg L, Claesson I, Sundfeldt K, Horvath G. External validation suggests Integrin beta 3 as prognostic biomarker in serous ovarian adenocarcinomas. BMC cancer. 2009; 9:336.
35. Partheen K, Levan K, Osterberg L, Claesson I, Fallenius G, Sundfeldt K, Horvath G. Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas. International journal of cancer. 2008; 123:2130-2137.
36. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer discovery. 2012; 2:401-404.
37. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Science signaling. 2013; 6:pl1.
38. Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. Emerging landscape of oncogenic signatures across human cancers. Nature genetics. 2013; 45:1127-1133.
39. Barger CJ, Zhang W, Hillman J, Stablewski AB, Higgins MJ, Vanderhyden BC, Odunsi K, Karpf AR. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression. Oncotarget. 2015; 6:27613-27627. doi: 10.18632/oncotarget.4546.
40. Woloszynska-Read A, Mhawech-Fauceglia P, Yu J, Odunsi K, Karpf AR. Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoterspecific and global DNA methylation status in ovarian cancer. Clinical cancer research. 2008; 14:3283-3290.
41. Woloszynska-Read A, Zhang W, Yu J, Link PA, Mhawech-Fauceglia P, Collamat G, Akers SN, Ostler KR, Godley LA, Odunsi K, Karpf AR. Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage. Clinical cancer research. 2011; 17:2170-2180.
42. Zhang W, Barger CJ, Link PA, Mhawech-Fauceglia P, Miller A, Akers SN, Odunsi K, Karpf AR. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer. Epigenetics. 2015; 10:736-748.
43. Gardiner-Garden M, Frommer M. CpG islands in vertebrate genomes. Journal of molecular biology. 1987; 196:261-282.
44. Dupont JM, Tost J, Jammes H, Gut IG. De novo quantitative bisulfite sequencing using the pyrosequencing technology. Analytical biochemistry. 2004; 333:119-127.
45. De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F, Boon T. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proceedings of the National Academy of Sciences of the United States of America. 1996; 93:7149-7153.
46. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004; 429:457-463.
47. Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE, Cui H, Feinberg AP, Lengauer C, Kinzler KW, Baylin SB, Vogelstein B. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature. 2002; 416:552-556.
48. Song L, James SR, Kazim L, Karpf AR. Specific method for the determination of genomic DNA methylation by liquid chromatography-electrospray ionization tandem mass spectrometry. Anal Chem. 2005; 77:504-510.
49. Doldo E, Costanza G, Agostinelli S, Tarquini C, Ferlosio A, Arcuri G, Passeri D, Scioli MG, Orlandi A. Vitamin A, cancer treatment and prevention: the new role of cellular retinol binding proteins. BioMed research international. 2015; 2015:624627.
50. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clinical cancer research. 2008; 14:5198-5208.
51. James SR, Cedeno CD, Sharma A, Zhang W, Mohler JL, Odunsi K, Wilson EM, Karpf AR. DNA methylation and nucleosome occupancy regulate the cancer germline antigen gene MAGEA11. Epigenetics. 2013; 8:849-863.
52. Link PA, Zhang W, Odunsi K, Karpf AR. BORIS/CTCFL mRNA isoform expression and epigenetic regulation in epithelial ovarian cancer. Cancer Immun. 2013; 13:6.
53. Link PA, Gangisetty O, James SR, Woloszynska-Read A, Tachibana M, Shinkai Y, Karpf AR. Distinct roles for histone methyltransferases G9a and GLP in cancer germline antigen gene regulation in human cancer cells and murine embryonic stem cells. Mol Cancer Res. 2009; 7:851-862.
54. James SR, Link PA, Karpf AR. Epigenetic regulation of X-linked cancer/germline antigen genes by DNMT1 and DNMT3b. Oncogene. 2006; 25:6975-6985.
55. Akers SN, Moysich K, Zhang W, Collamat Lai G, Miller A, Lele S, Odunsi K, Karpf AR. LINE1 and Alu repetitive element DNA methylation in tumors and white blood cells from epithelial ovarian cancer patients. Gynecologic oncology. 2014; 132:462-467.
56. Chen YT, Hsu M, Lee P, Shin SJ, Mhawech-Fauceglia P, Odunsi K, Altorki NK, Song CJ, Jin BQ, Simpson AJ, Old LJ. Cancer/testis antigen CT45: analysis of mRNA and protein expression in human cancer. International journal of cancer. 2009; 124:2893-2898.
57. Clark SJ, Harrison J, Paul CL, Frommer M. High sensitivity mapping of methylated cytosines. Nucleic acids research. 1994; 22:2990-2997.